For example, the switch of immunosuppressant from cyclosporin A to the mTOR inhibitor rapamycin (Sirolimus) elicited KS regression in transplant patients, and it is now the first line of treatment for transplant KS (Stallone et al., 2005). Here, MTOR is linked to Kaposi's sarcoma.